Table 2 Currently FDA approved and preclinical therapeutic targets in the translational pipeline targeting EMT-related pathways
From: The translational significance of epithelial-mesenchymal transition in head and neck cancer
Agent | Type | Target/MOA | Combinational regimen | Trial | Clinical stage | References |
|---|---|---|---|---|---|---|
Cetuximab | MAb | EGFR-Selective Tyrosine Kinase Inhibitor | Radiation; Cisplatin (Metastatic) | Bonner; EXTREME | FDA Approved 2006; 2008 (Metastatic) | |
PD173074 | Small molecule | FGFR1; Nonselective Tyrosine Kinase Inhibitor | -- | -- | Preclinical | [113] |
Colecoxib | Small molecule | COX-2 Inhibitor | -- | -- | Preclinical | [69] |
NS-398 | Small molecule | COX-2 Inhibitor | -- | -- | Preclinical | [69] |
SC-91 | Small molecule | COX-2 Inhibitor | -- | -- | Preclinical | [69] |
Trans RA | Small molecule | RAR agonist/TGFβ Antagonist | -- | -- | Preclinical | [115] |
AZ64 | Small molecule | Trkβ; Nonselective Tyrosine Kinase Inhibitor | Cisplatin | -- | Preclinical | [67] |
Bivatuzumab-DM1 | MAb | CD44v6-Maytansionoid Cytotoxin mertansine | -- | -- | Phase 1 (discontinued) |